Teleflex's (TFX) "Sell (D+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Teleflex's stock has been reaffirmed with a "sell (D+)" rating by Weiss Ratings, while other analysts have varied views, with Royal Bank Of Canada and Mizuho assigning a "sector perform" and "neutral" rating respectively.
• The company reported $3.73 EPS for the last quarter, surpassing estimates, with a revenue increase of 4.2% year-over-year, reaching $780.90 million.
• Insider trading activity showed significant purchasing from Director Andrew A. Krakauer and CEO Liam Kelly, indicating increased confidence in the company's prospects.

Teleflex (NYSE:TFX - Get Free Report)'s stock had its "sell (d+)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts also recently issued research reports about the company. Royal Bank Of Canada increased their price objective on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a report on Friday, August 1st. Zacks Research cut Teleflex from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. Mizuho upped their target price on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a research report on Friday, August 1st. Wall Street Zen cut Teleflex from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 15th. Finally, Wells Fargo & Company decreased their target price on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $141.57.

Teleflex Stock Up 1.3%

Shares of TFX traded up $1.61 during mid-day trading on Wednesday, reaching $128.50. The company's stock had a trading volume of 318,146 shares, compared to its average volume of 761,292. Teleflex has a 12-month low of $108.90 and a 12-month high of $241.41. The stock has a market cap of $5.68 billion, a PE ratio of 30.24, a price-to-earnings-growth ratio of 1.78 and a beta of 1.05. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The company's 50 day moving average is $124.12 and its 200 day moving average is $124.54.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business had revenue of $780.90 million for the quarter, compared to the consensus estimate of $771.53 million. During the same quarter in the prior year, the business posted $3.42 EPS. The business's revenue for the quarter was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities analysts anticipate that Teleflex will post 13.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Teleflex news, Director Andrew A. Krakauer purchased 1,000 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $115.25 per share, with a total value of $115,250.00. Following the acquisition, the director directly owned 7,192 shares of the company's stock, valued at $828,878. This represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Liam Kelly purchased 1,500 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $115.07 per share, with a total value of $172,605.00. Following the completion of the acquisition, the chief executive officer directly owned 45,267 shares in the company, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 5,500 shares of company stock worth $633,590. 1.40% of the stock is currently owned by insiders.

Institutional Trading of Teleflex

Several hedge funds have recently modified their holdings of TFX. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock valued at $26,000 after buying an additional 153 shares during the period. Banque Cantonale Vaudoise acquired a new stake in shares of Teleflex in the 1st quarter valued at approximately $27,000. Costello Asset Management INC acquired a new stake in shares of Teleflex in the 1st quarter valued at approximately $28,000. Brooklyn Investment Group lifted its holdings in shares of Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock valued at $29,000 after buying an additional 150 shares during the period. Finally, Allworth Financial LP lifted its holdings in shares of Teleflex by 504.8% in the 1st quarter. Allworth Financial LP now owns 254 shares of the medical technology company's stock valued at $34,000 after buying an additional 212 shares during the period. 95.62% of the stock is owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.